Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.68 |
| ▸ | NPC1 | O15118 | 4/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.68 |
| ▸ | POLB | P06746 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | HPGD | P15428 | 3/20 | 0.65 |
| ▸ | CASP3 | P42574 | 2/20 | 0.65 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.65 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.65 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.65 |
| ▸ | PTPN1 | P18031 | 13/20 | 0.63 |
| ▸ | PTPN5 | P54829 | 13/20 | 0.63 |
| ▸ | PTPN2 | P17706 | 11/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26952136 | 0.88 | CASP3 (0.68) | SMN1; SMN2KDM4ENPC1RAB9APOLB | |
| SCHEMBL20685031 | 0.84 | RAB9A (0.72) | SMN1; SMN2KDM4ENPC1RAB9APOLB | |
| SCHEMBL14302714 | 0.82 | TP53 (0.70) | SMN1; SMN2KDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL3196281 | 0.81 | ALDH1A1 (0.76) | SMN1; SMN2KDM4ENPC1RAB9APOLB | |
| SCHEMBL2243174 | 0.81 | NPC1 (1.00) | SMN1; SMN2KDM4ENPC1RAB9APOLB | |
| SCHEMBL1660542 | 0.81 | NPC1 (0.67) | SMN1; SMN2KDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL2245045 | 0.80 | ALDH1A1 (0.60) | SMN1; SMN2KDM4ENPC1RAB9APOLB | |
| SCHEMBL13528498 | 0.80 | NPC1 (0.72) | SMN1; SMN2KDM4ENPC1RAB9APOLB | |
| SCHEMBL2244889 | 0.80 | BCHE (0.60) | SMN1; SMN2KDM4ENPC1RAB9APOLB | |
| SCHEMBL2240267 | 0.79 | KDM4E (0.58) | SMN1; SMN2KDM4ENPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720836-B1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8580780-B2 | 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist | ELI LILLY AND COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2479168-A1 | 6-Substituted 2,3,4,5-Tetrahydro-1H-Benzo [d]Azepines as 5-HT2C Receptor Agonists | ELI LILLY AND COMPANY (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | ELI LILLY AND COMPANY (US) | 2012-02-02 | — | — | US | disclosed |
| US-8022062-B2 | 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists | ELI LILLY AND COMPANY (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ARRAY BIOPHARMA, INC. | 2009-04-16 | — | — | US | disclosed |
| CN-1934088-A | As 5-HT2c6-substituted 2,3,4, 5-tetrahydro-1H-benzo [ d ] receptor agonists]Aza * | LILLY CO ELI (US) | 2007-03-21 | — | — | CN | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR5A, HTR4 | SMN1; SMN2 1853/4885KDM4E 1208/4885NPC1 2664/4885 |
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | HTR2C, HTR4, HTR1A | SMN1; SMN2 2954/4885KDM4E 623/4885NPC1 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.